- Source : Press Release
- Date : 2021-01-15
- Event type : Marketed
- Companies : Catalent, Inc.
Catalent Entered Into a Long-term Supply Agreement with Acorda for INBRIJA
"Catalent has also entered into a long-term supply agreement with Acorda Therapeutics to continue commercial manufacture of INBRIJA® (levodopa inhalation powder) from the Chelsea facility. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine."
Sourced from the news: https://www.pharmacircle.com/one_news.php?id=560234